The Shift of Medical Devices to a Home Setting

Wednesday, November 2, 2016 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 2, 2016 /PRNewswire/ -- - One of the major changes in the medical device

sector is the continuously growing emphasis on home health care through wearable device and remote monitoring devices. Technology now allows patients a much more flexible approach to therapy, one that does not diminish their life styles as previously.
A recent research report by Meticulous Research estimates that the global home medical devices market is expected to reach $48.47 billion by 2022 with a CAGR of 7.8% over the period of 2016 to 2022. Biotricity Inc. (OTC: BTCY), Zimmer Biomet Holdings Inc. (NYSE: ZBH), Baxter International Inc. (NYSE: BAX), Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT) 

As a result, a recent trend of sophisticated wearables with remote monitoring capabilities has emerged. In addition, medical devices and home healthcare equipment originally designed for exclusive use in hospitals and clinical settings by trained professionals are being redesigned for use by patients at home. The report by Meticulous Research also points out that the shift to home healthcare is one of several strategies being deployed to reduce the inevitable growth in the cost of delivering healthcare services.

Biotricity Inc. (OTCQB: BTCY) is focusing on biometric monitoring solutions for medical, healthcare and consumer use. Biotricity's remote patient technologies a beneficial for a variety of chronic illnesses that provide doctors with diagnostic tools. Earlier in October, the company announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a key component of one of its solutions - Bioflux, an ECG monitoring device that will monitor a patient's heart rhythm and send data in real-time to a 24-hour monitoring lab.

On November 1st, Biotricity Inc. announced appointment of Dr. Rony Shimony to its Board of Advisors. Shimony is an internationally recognized clinical cardiologist who brings to the company over twenty-five years of experience in cardiac patient care and related technology. Dr. Shimony is the director of Clinical Cardiology at Mount Sinai West, which is part of the internationally renowned Mount Sinai Health System that encompasses a full range of cardiovascular services, including cardiovascular prevention, complex cardiac interventions, full electrophysiology services, heart failure and heart transplant program and more.

Waqaas Al-Siddiq, president and CEO of Biotricity Inc., said in a statement, "As heart disease remains the #1 killer globally, representing 31 percent of all deaths worldwide, we are thrilled to have Dr. Shimony bring his expertise to our advisory board where he will collaborate with other talented and accomplished members to help drive our strategic vision of evolving the healthcare industry." In additional news, on October 10th, 2016, Capital Ladder Advisory Group in their comparative analysis and valuation report, assigned a $6 price target to Biotricity Inc.

Zimmer Biomet Holdings Inc. (NYSE: ZBH) is a medical device company engaged in manufacturing and marketing a wide range of medical solutions, like orthopaedic reconstructive products, sports medicine, biologics, extremities and trauma products, spine, bone healing, as well as dental implants, and related surgical products. Zimmer Biomet recently announced the acquisition of RespondWell, an award-winning telerehabilitation technology designed to provide personalized, clinician-supervised post-surgical physical therapy in the comfort of a patient's home. The technology's capability designed to enhance patient compliance with physical therapy and improve the quality of recovery remotely.

Baxter International Inc. (NYSE: BAX) provides a portfolio of essential renal and hospital products, including acute and in-center dialysis, sterile intravenous (IV) solutions, infusion systems and devices, and more. Last month the company was named a winner of the 15th annual Chicago Innovation Awards for its recently launched AMIA automated peritoneal dialysis (APD) system with SHARESOURCE remote patient management platform. The system is a two-way, cloud-based telehealth platform designed to promote home peritoneal dialysis (PD) therapy. Currently the AMIA is the first and only APD medical device to include patient-centric features that help guide end-stage renal disease (ESRD) patients through their home therapy, while allowing their healthcare providers to remotely view and manage their therapy.

Boston Scientific Corporation (NYSE: BSX) is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The company has several remote patient monitoring devices in catalog - the BodyGuardian Remote Monitoring System for example helps physicians refine patients' care giving patients freedom to do so remotely from home. The small discreet repositionable wireless sensor offers full convertibility between mobile cardiac telemetry (MCT) and cardiac event monitoring (CEM).

Abbott Laboratories (NYSE: ABT) is one of the largest science-based, diversified healthcare companies, and has recognized the importance of wearable and remote monitoring devices. Abbott's Diabetes Care business worked on glucose monitoring systems such as the FreeStyleŽ Libre Flash Glucose Monitoring System, a sensor-based glucose monitoring solution that's currently available to people with diabetes in Europe. It is not clear when the device will launch in the United States, as the company awaits an approval from the FDA.

Subscribe Now! Watch us report from NYSE

For "The Latest Buzz in Financial News", SIGN UP & Visit:

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. has signed a four-month financial news dissemination and pr services agreement for ten thousand dollars directly from the biotricity inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. agreed to a four-month financial news dissemination and pr services agreement for ten thousand restricted shares and twenty thousand warrants directly from biotricity inc. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: Danny A, , +1-877-601-1879 Url:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store